ZyGem said today that it has signed a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases to develop simplified sample processing tools for biothreat agent detection.

As part of the CRADA, ZyGem and USAMRIID will jointly develop, test, and validate new solutions to rapidly and efficiently extract DNA and other nucleic acids in order to detect biothreat agents and other pathogens from a variety of sample matrices, including buffer, serum, whole blood, and swabs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.